Axsome Therapeutics Inc

Axsome Therapeutics Inc a biopharmaceutical company engages in the development of novel therapies for central nervous system CNS disorders in the United States The companys product pipeline includes AXS05 a therapeutic for the treatment of major depressive disorder and resistant depression disorders and that is in the Phase III clinical trial to treat Alzheimers disease agitation as well as that has completed phase II clinical trial for the treatment of smoking cessation It is also developing AXS07 a novel oral rapidly absorbed multimechanistic and investigational medicine that has completed two Phase III trials for the acute treatment of migraine AXS12 a selective and potent norepinephrine reuptake inhibitor which is in Phase III trial to treat narcolepsy and AXS14 a novel oral and investigational medicine that is in Phase III trial for the treatment of fibromyalgia Axsome Therapeutics Inc has a research collaboration agreement with Duke University for evaluating AXS05 in smoking cessation The company was incorporated in 2012 and is based in New York New York